James L, Stout N, Avery T, Stein S, Sands K, Septimus E
JAMA Netw Open. 2025; 8(3):e250341.
PMID: 40063027
PMC: 11894500.
DOI: 10.1001/jamanetworkopen.2025.0341.
Pesonen M, Kankaanpaa E
Clinicoecon Outcomes Res. 2025; 17:115-128.
PMID: 40028500
PMC: 11872088.
DOI: 10.2147/CEOR.S509349.
Dijk S, Korf M, Labrecque J, Pandya A, Ferket B, Hallsson L
Med Decis Making. 2025; :272989X241310898.
PMID: 39846352
PMC: 11894903.
DOI: 10.1177/0272989X241310898.
Tam J, Crippen A, Friedman A, Jeon J, Colston D, Fleischer N
JAMA Health Forum. 2024; 5(12):e244445.
PMID: 39705045
PMC: 11662258.
DOI: 10.1001/jamahealthforum.2024.4445.
Dawkins B, Shinkins B, Ensor T, Jayne D, Meads D
Int J Technol Assess Health Care. 2024; 40(1):e59.
PMID: 39552285
PMC: 11579673.
DOI: 10.1017/S0266462324000618.
A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET/CT for Therapy Response Monitoring in Oncology.
van Mossel S, de Feria Cardet R, de Geus-Oei L, Vriens D, Koffijberg H, Saing S
Pharmacoeconomics. 2024; 43(2):133-151.
PMID: 39488797
PMC: 11782410.
DOI: 10.1007/s40273-024-01447-y.
Do COVID-19 Infectious Disease Models Incorporate the Social Determinants of Health? A Systematic Review.
John-Baptiste A, Moulin M, Li Z, Hamilton D, Crichlow G, Eisenkraft Klein D
Public Health Rev. 2024; 45:1607057.
PMID: 39450316
PMC: 11499127.
DOI: 10.3389/phrs.2024.1607057.
Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning.
Crosland P, Marshall D, Hosseini S, Ho N, Vacher C, Skinner A
Pharmacoeconomics. 2024; 42(12):1301-1315.
PMID: 39354214
PMC: 11564312.
DOI: 10.1007/s40273-024-01434-3.
Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care.
Gye A, De Abreu Lourenco R, Goodall S
Pharmacoeconomics. 2024; 42(12):1359-1371.
PMID: 39243347
PMC: 11564325.
DOI: 10.1007/s40273-024-01430-7.
Pharmaceutical intervention for hypertension in a rural district of the Republic of Zambia: a model-based economic evaluation.
Yokobori Y, Deidda M, Manca F
BMJ Open. 2024; 14(9):e084575.
PMID: 39237286
PMC: 11381728.
DOI: 10.1136/bmjopen-2024-084575.
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.
Campbell J, Henson G, Ngwa V, Ahmad H, Taylor B, van der Mei I
Pharmacoeconomics. 2024; 43(2):223-239.
PMID: 39095665
PMC: 11782298.
DOI: 10.1007/s40273-024-01417-4.
Impact of Structural Differences on the Modeled Cost-Effectiveness of Noninvasive Prenatal Testing.
Salisbury A, Pearce A, Howard K, Norris S
Med Decis Making. 2024; 44(7):811-827.
PMID: 39092556
PMC: 11492563.
DOI: 10.1177/0272989X241263368.
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia.
Sutton A, Lupu D, Bergin S, Holland T, McAdams S, Dadwal S
Pharmacoeconomics. 2024; 42(9):1029-1045.
PMID: 38955978
PMC: 11343789.
DOI: 10.1007/s40273-024-01409-4.
ROBVALU: a tool for assessing risk of bias in studies about people's values, utilities, or importance of health outcomes.
Karam S, Zhang Y, Pardo-Hernandez H, Siebert U, Koopman L, Noyes J
BMJ. 2024; 385:e079890.
PMID: 38866410
PMC: 11167527.
DOI: 10.1136/bmj-2024-079890.
Cost-effectiveness of one-stop-shop [F]Fluorocholine PET/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism.
van Mossel S, Saing S, Appelman-Dijkstra N, Quak E, Schepers A, Smit F
Eur J Nucl Med Mol Imaging. 2024; 51(12):3585-3595.
PMID: 38837058
PMC: 11457719.
DOI: 10.1007/s00259-024-06771-1.
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
Herring W, Gallagher M, Shah N, Morse K, Mladsi D, Dong O
Pharmacoeconomics. 2024; 42(6):693-714.
PMID: 38684631
PMC: 11126463.
DOI: 10.1007/s40273-024-01385-9.
Current and Projected Mortality and Hospitalization Rates Associated With Conditional Cash Transfer, Social Pension, and Primary Health Care Programs in Brazil, 2000-2030.
Aransiola T, Cavalcanti D, Ordonez J, Hessel P, Moncayo A, Chivardi C
JAMA Netw Open. 2024; 7(4):e247519.
PMID: 38648059
PMC: 11036142.
DOI: 10.1001/jamanetworkopen.2024.7519.
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review.
Grand T, Ren S, Hall J, Astrom D, Regnier S, Thokala P
Pharmacoeconomics. 2024; 42(6):619-631.
PMID: 38616217
PMC: 11126517.
DOI: 10.1007/s40273-024-01370-2.
A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations.
Wang J, Pouwels X, Ramaekers B, Frederix G, van Lieshout C, Hoogenveen R
Pharmacoeconomics. 2024; 42(7):797-810.
PMID: 38613660
PMC: 11180025.
DOI: 10.1007/s40273-024-01376-w.
Decision-analytic models based on real-world data to assess treatment sequencing in inflammatory bowel disease: A complementary approach to clinical trials.
Benech N, Kirchgesner J
United European Gastroenterol J. 2024; 12(5):535-536.
PMID: 38568741
PMC: 11176904.
DOI: 10.1002/ueg2.12570.